- Home
- KUKE vs NTRB Comparison
KUKE vs NTRB Comparison
Compare KUKE & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- NTRB
- Stock Information
- Founded
- KUKE 2002
- NTRB 2016
- Country
- KUKE China
- NTRB United States
- Employees
- KUKE N/A
- NTRB N/A
- Industry
- KUKE Other Consumer Services
- NTRB Industrial Specialties
- Sector
- KUKE Real Estate
- NTRB Health Care
- Exchange
- KUKE Nasdaq
- NTRB Nasdaq
- Market Cap
- KUKE 21.2M
- NTRB 77.9M
- IPO Year
- KUKE 2021
- NTRB N/A
- Fundamental
- Price
- KUKE $0.31
- NTRB $4.08
- Analyst Decision
- KUKE
- NTRB
- Analyst Count
- KUKE 0
- NTRB 0
- Target Price
- KUKE N/A
- NTRB N/A
- AVG Volume (30 Days)
- KUKE 101.1K
- NTRB 30.1K
- Earning Date
- KUKE 12-31-2024
- NTRB 12-04-2024
- Dividend Yield
- KUKE N/A
- NTRB N/A
- EPS Growth
- KUKE N/A
- NTRB N/A
- EPS
- KUKE N/A
- NTRB N/A
- Revenue
- KUKE $14,784,158.00
- NTRB $2,021,771.00
- Revenue This Year
- KUKE N/A
- NTRB N/A
- Revenue Next Year
- KUKE N/A
- NTRB N/A
- P/E Ratio
- KUKE N/A
- NTRB N/A
- Revenue Growth
- KUKE 10.48
- NTRB N/A
- 52 Week Low
- KUKE $0.23
- NTRB $2.22
- 52 Week High
- KUKE $4.07
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- KUKE 40.34
- NTRB 40.82
- Support Level
- KUKE $0.30
- NTRB $3.87
- Resistance Level
- KUKE $0.39
- NTRB $4.80
- Average True Range (ATR)
- KUKE 0.05
- NTRB 0.51
- MACD
- KUKE 0.01
- NTRB 0.04
- Stochastic Oscillator
- KUKE 20.79
- NTRB 21.21
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.